CN1551728A - 转导造血祖细胞的生成 - Google Patents

转导造血祖细胞的生成 Download PDF

Info

Publication number
CN1551728A
CN1551728A CNA028174879A CN02817487A CN1551728A CN 1551728 A CN1551728 A CN 1551728A CN A028174879 A CNA028174879 A CN A028174879A CN 02817487 A CN02817487 A CN 02817487A CN 1551728 A CN1551728 A CN 1551728A
Authority
CN
China
Prior art keywords
cell
cells
described method
nucleic acid
exogenous nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028174879A
Other languages
English (en)
Chinese (zh)
Inventor
G
G·西蒙子
J·莫里
G·凡宁
�������ɭ
J·麦克弗森
S·庞德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J&j Research Holding Co ltd
Original Assignee
J&j Research Holding Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J&j Research Holding Co ltd filed Critical J&j Research Holding Co ltd
Publication of CN1551728A publication Critical patent/CN1551728A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA028174879A 2001-07-10 2002-07-10 转导造血祖细胞的生成 Pending CN1551728A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30428301P 2001-07-10 2001-07-10
US60/304,283 2001-07-10
US34339201P 2001-10-22 2001-10-22
US60/343,392 2001-10-22

Publications (1)

Publication Number Publication Date
CN1551728A true CN1551728A (zh) 2004-12-01

Family

ID=26973926

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028174879A Pending CN1551728A (zh) 2001-07-10 2002-07-10 转导造血祖细胞的生成

Country Status (9)

Country Link
US (1) US20030082158A1 (enExample)
EP (1) EP1418814A4 (enExample)
JP (1) JP2005521632A (enExample)
KR (1) KR20040084885A (enExample)
CN (1) CN1551728A (enExample)
BR (1) BR0211066A (enExample)
CA (1) CA2453187A1 (enExample)
IL (1) IL159777A0 (enExample)
WO (1) WO2003006612A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
KR101015913B1 (ko) 2001-07-10 2011-02-23 존슨 앤드 존슨 리서치 피티와이 리미티드 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도
ES2358187T3 (es) 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
US7799324B2 (en) 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
GB2399572B (en) * 2001-12-07 2006-06-07 Robarts Res Inst Hematopoietic cells from human embryonic stem cells
WO2004041220A2 (en) * 2002-11-06 2004-05-21 L'oreal Composition containing a semi-crystalline polymer and a pasty fatty substance
FR2846554B1 (fr) * 2002-11-06 2007-02-09 Oreal Composition contenant un polymere semi-cristallin et un corps gras pateux
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
WO2012074068A1 (ja) 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
CN116583594B (zh) 2020-10-14 2025-05-23 奥瑟姆健康公司 用于骨髓的提取和低温保藏的系统和方法
WO2022133282A1 (en) 2020-12-18 2022-06-23 Ossium Health, Inc. Methods of cell therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500357A (en) * 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5911983A (en) * 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
ES2358187T3 (es) * 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
KR101015913B1 (ko) * 2001-07-10 2011-02-23 존슨 앤드 존슨 리서치 피티와이 리미티드 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도

Also Published As

Publication number Publication date
US20030082158A1 (en) 2003-05-01
BR0211066A (pt) 2006-08-29
KR20040084885A (ko) 2004-10-06
IL159777A0 (en) 2004-06-20
EP1418814A4 (en) 2006-10-11
JP2005521632A (ja) 2005-07-21
CA2453187A1 (en) 2003-01-23
WO2003006612A2 (en) 2003-01-23
EP1418814A2 (en) 2004-05-19
WO2003006612A3 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
US20230203537A1 (en) Stable pseudotyped lentiviral particles and uses thereof
Rosenzweig et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells
US7345025B2 (en) Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
Hütter Stem cell transplantation in strategies for curing HIV/AIDS
CN1127527A (zh) 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
HK1046928A1 (en) Veto cells effective in preventing graft rejection and devoid of graft versus host potential
CN1551728A (zh) 转导造血祖细胞的生成
US20120058092A1 (en) Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
Valtieri et al. Efficient transfer of selectable and membrane reporter genes in hematopoietic progenitor and stem cells purified from human peripheral blood
CN1856506A (zh) 向哺乳动物中移植淋巴造血细胞的方法
Stevenson et al. A herpesvirus saimiri-based gene therapy vector with potential for use in cancer immunotherapy
Poznansky et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat
Ngok et al. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS
US20060051866A1 (en) Means of producing and utilising a population of disease specific cytotoxic t-lymphocytes
Banda et al. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model
Ueda et al. Cloning and functional analysis of the rhesus macaque ABCG2 gene: Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo
JP7612617B2 (ja) 細胞性免疫及び体液性免疫を誘導するための同種異系ｔ細胞ベースのｈｉｖワクチン
EP0716710B1 (en) Methods of suppressing immune response by gene therapy
Hariharan et al. Human immunodeficiency virus infection of human placental cord blood CD34+ AC133+ stem cells and their progeny
Bunnell et al. Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34+ cells
JP2002522067A (ja) 一群の抗原を発現する操作された抗原提示細胞およびその使用
Winterhalter CRISPR/Cas9 based HLA reduction of T cells for universal T cell therapy
Berson et al. Selection of murine lymphoid and hematopoietic cells using polystyrene tissue culture devices containing covalently immobilized antibody
Boyd et al. Critical steps in the implementation of hematopoietic progenitor-cell gene therapy using ribozyme vectors: a laboratory protocol
KR101043871B1 (ko) 동종 제대혈 혈청 또는 혈장을 사용하는 유전자 도입 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication